Table 2.
Patient | Reason for withdrawal | Day (period) of withdrawal | Treatment group |
---|---|---|---|
LAS-11* | AE—neurological | Day 1 (T1) | 2 (RR) |
LAS-23 | Withdrawal of owner consent | Day 19 (T1/T2) | 2 (RR) |
LAS-26* | AE—gastrointestinal—emesis | Day 4 (T1) | 1 (PP) |
LAS-28 | AE—gastrointestinal—emesis | Day 23 (T2) | 2 (RR) |
LAS-37* | AE—gastrointestinal—emesis | Day 11 (T1) | 2 (RR) |
LAS-38* | AE—gastrointestinal—emesis | Day 15 (T1) | 1 (PP) |
LAS-40 | AE—integumentary | Day 25 (T2) | 3 (RP) |
LAS-63 | AE—gastrointestinal—emesis | Day 22 (T2) | 1 (PP) |
LAS-86 | AE—gastrointestinal—emesis | Day 16 (T1) | 3 (RP) |
LAS-87 | Recurrence of behavioral disorder—defecation | Day 22 (T2) | 2 (RR) |
LAS patient identification code corresponding to patients enrolled at North Carolina State University, AE adverse event, T1 treatment period 1, T2 treatment period 2, P placebo, R robenacoxib.
*Excluded from the PP analysis due to significant deficiencies in dosing.